In our present study on stage IV melanoma patients, a higher level of tumor cell HLA class I expression was detected by two of the four antibodies used: HC10, recognizing mainly HLA-B and -C antigens and the pan-HLA class I EMR8-5; this result is similar to our findings in patients receiving ipilimumab therapy [25]. Here, CYCSP25 is linked to melanoma.